BioSpace12h
Lilly, Insitro Ink Unique AI Deal, Eye Novel Treatments for Metabolic Diseases
In a departure from most deals, startup insitro will in-license Lilly’s delivery technology for its investigational ...
BioSpace13h
Big Pharma’s Interest Grows in Evolving Cell and Gene Therapy Sector
Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand ...
BioSpace14h
Manager’s Toolbox: How Resilience Can Help You Bounce Back From Adversity
Managers face a variety of challenges during their careers. Instead of falling into fight or flight, develop resilience to ...
BioSpace14h
Stealth’s Ultrarare Disease Candidate Might Not Meet Bar for Approval: FDA
The FDA’s reviewers pointed out that Stealth’s elamipretide missed its primary efficacy endpoints in the main study used to ...
BioSpace15h
Zealand Hit With CRL for Ultrarare Genetic Disease Treatment
The rejection is related to the timing of the FDA’s reinspection of Zealand’s third-party manufacturer, which previously had ...
BioSpace22h
Lilly’s Sprawling Obesity Clinical Program Underscores Challenges for Biotechs
Eli Lilly’s CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as ...